Literature DB >> 17804834

LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8.

W C Nichols1, V E Elsaesser, N Pankratz, M W Pauciulo, D K Marek, C A Halter, A Rudolph, C W Shults, T Foroud.   

Abstract

BACKGROUND: Pathogenic mutations in the leucine-rich repeat kinase 2 gene (LRRK2) have been found to cause typical, later-onset Parkinson disease (PD). Although G2019S is the most common mutation, other mutations have also been reported. It is critical to catalog the types of mutations found in LRRK2 that can cause PD, so as to provide insight regarding disease susceptibility and potential novel treatments.
METHODS: We performed a comprehensive study of all 51 exons of the LRRK2 gene in one PD patient from each of 88 multiplex PD families who had the highest family-specific multipoint lod score at the LRRK2 locus from a cohort of 430 PD families without the G2019S mutation.
RESULTS: Five families (5.7%) harbored what seem to be novel, pathogenic mutations (L1795F, I1192V, E10K, E334K, Q1111H). Three of these apparent mutations were in known, functional domains of the LRRK2 protein, where other studies have also identified disease producing mutations. However, two of the novel variants were found in the N-terminal region of LRRK2, where no pathogenic substitutions have yet been reported. Similar to previous studies, all subjects with an LRRK2 mutation had classic symptoms of PD and typical, later age at onset.
CONCLUSIONS: We have identified five novel variants in LRRK2, with two of these in the N-terminal region of LRRK2, where no pathogenic substitutions have been previously reported. If confirmed to be causative, these mutations would broaden the potential mechanisms whereby mutations in LRRK2 result in Parkinson disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17804834     DOI: 10.1212/01.wnl.0000278115.50741.4e

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  24 in total

1.  Lrrk2 p.Q1111H substitution and Parkinson's disease in Latin America.

Authors:  Ignacio F Mata; Greggory J Wilhoite; Dora Yearout; Justin A Bacon; Mario Cornejo-Olivas; Pilar Mazzetti; Victoria Marca; Olimpio Ortega; Oscar Acosta; Carlos Cosentino; Luis Torres; Angel C Medina; Carolina Perez-Pastene; Fernando Díaz-Grez; Carles Vilariño-Güell; Pablo Venegas; Marcelo Miranda; Osvaldo Trujillo-Godoy; Luis Layson; Rodrigo Avello; Elena Dieguez; Victor Raggio; Federico Micheli; Claudia Perandones; Victoria Alvarez; Juan Segura-Aguilar; Matthew J Farrer; Cyrus P Zabetian; Owen A Ross
Journal:  Parkinsonism Relat Disord       Date:  2011-05-31       Impact factor: 4.891

2.  LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease.

Authors:  Chen Yao; Rabih El Khoury; Wen Wang; Tara A Byrd; Elizabeth A Pehek; Colin Thacker; Xiongwei Zhu; Mark A Smith; Amy L Wilson-Delfosse; Shu G Chen
Journal:  Neurobiol Dis       Date:  2010-04-09       Impact factor: 5.996

3.  Structural and functional in silico analysis of LRRK2 missense substitutions.

Authors:  Fernando Cardona; Marta Tormos-Pérez; Jordi Pérez-Tur
Journal:  Mol Biol Rep       Date:  2014-02-02       Impact factor: 2.316

4.  Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset.

Authors:  W C Nichols; N Pankratz; D K Marek; M W Pauciulo; V E Elsaesser; C A Halter; A Rudolph; J Wojcieszek; R F Pfeiffer; T Foroud
Journal:  Neurology       Date:  2008-11-05       Impact factor: 9.910

5.  Clinical correlates of depressive symptoms in familial Parkinson's disease.

Authors:  Nathan Pankratz; Karen S Marder; Cheryl A Halter; Alice Rudolph; Cliff W Shults; William C Nichols; Tatiana Foroud
Journal:  Mov Disord       Date:  2008-11-15       Impact factor: 10.338

6.  Variation in GIGYF2 is not associated with Parkinson disease.

Authors:  W C Nichols; D K Kissell; N Pankratz; M W Pauciulo; V E Elsaesser; K A Clark; C A Halter; A Rudolph; J Wojcieszek; R F Pfeiffer; T Foroud
Journal:  Neurology       Date:  2009-03-11       Impact factor: 9.910

7.  Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations.

Authors:  N Pankratz; D K Kissell; M W Pauciulo; C A Halter; A Rudolph; R F Pfeiffer; K S Marder; T Foroud; W C Nichols
Journal:  Neurology       Date:  2009-07-28       Impact factor: 9.910

8.  Ancient origin of the Parkinson disease gene LRRK2.

Authors:  Ignacio Marín
Journal:  J Mol Evol       Date:  2008-06-04       Impact factor: 2.395

9.  LRRK2 mutations and risk variants in Japanese patients with Parkinson's disease.

Authors:  Cyrus P Zabetian; Mitsutoshi Yamamoto; Alexis N Lopez; Hiroshi Ujike; Ignacio F Mata; Yuishin Izumi; Ryuji Kaji; Hirofumi Maruyama; Hiroyuki Morino; Masaya Oda; Carolyn M Hutter; Karen L Edwards; Gerard D Schellenberg; Debby W Tsuang; Dora Yearout; Eric B Larson; Hideshi Kawakami
Journal:  Mov Disord       Date:  2009-05-15       Impact factor: 10.338

10.  Genomewide association study for onset age in Parkinson disease.

Authors:  Jeanne C Latourelle; Nathan Pankratz; Alexandra Dumitriu; Jemma B Wilk; Stefano Goldwurm; Gianni Pezzoli; Claudio B Mariani; Anita L DeStefano; Cheryl Halter; James F Gusella; William C Nichols; Richard H Myers; Tatiana Foroud
Journal:  BMC Med Genet       Date:  2009-09-22       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.